HOTAIR rs920778 polymorphism is associated with ovarian cancer susceptibility and poor prognosis in a Chinese population.
OBJECTIVE
The aim of this study was to determine if HOTAIR rs920778 polymorphism is associated with ovarian cancer susceptibility and prognosis.


METHODS
The data were obtained from two independent groups including 329 ovarian cancer patients and 680 cancer-free, age-matched women. Blood samples were collected and genomic DNA was extracted for genotyping.


RESULTS
TT genotype and T allele of HOTAIR rs920778 were significantly associated with a decreased ovarian cancer risk (p = 0.0004 and p < 0.0001, respectively), which associated with advanced tumor stage, lymph node metastasis and poor prognosis. Moreover, TT and TC carriers obtained a much shorter survival (p = 0.026).


CONCLUSIONS
These findings propose that HOTAIR rs920778 polymorphism influences ovarian cancer susceptibility and prognosis, and further studies are warranted in other populations.
Department of Obstetrics & Gynecology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.|Ovarian & Cervical Disease Clinical Treatment Center of Henan Province, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.
Haifeng
H
Qiu
Department of Obstetrics & Gynecology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.|Ovarian & Cervical Disease Clinical Treatment Center of Henan Province, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.
Xiujuan
X
Wang
Department of Obstetrics & Gynecology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.|Ovarian & Cervical Disease Clinical Treatment Center of Henan Province, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.
Ruixia
R
Guo
Department of Obstetrics & Gynecology, the Affiliated Hospital of Jiangnan University & the Fourth's People's Hospital of Wuxi, Wuxi, 214062, China.
Qiuli
Q
Liu
Department of Obstetrics & Gynecology, the Affiliated Hospital of Jiangnan University & the Fourth's People's Hospital of Wuxi, Wuxi, 214062, China.
Yuan
Y
Wang
Department of Obstetrics & Gynecology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.|Ovarian & Cervical Disease Clinical Treatment Center of Henan Province, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.
Zhongfu
Z
Yuan
Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.
Jing
J
Li
Department of Obstetrics & Gynecology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.|Ovarian & Cervical Disease Clinical Treatment Center of Henan Province, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.
Huirong
H
Shi
D000328:Adult; D000368:Aged; D000483:Alleles; D044466:Asian People / Q000235:genetics*; D016022:Case-Control Studies; D002681:China; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D016017:Odds Ratio; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality* / Q000628:therapy; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D062085:RNA, Long Noncoding / Q000235:genetics*
C561566:HOTAIR long untranslated RNA, human; D062085:RNA, Long Noncoding
HOTAIR; cancer susceptibility; long noncoding RNA; ovarian cancer; prognosis; rs920778 polymorphism